These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 6840181)
21. Oral dosage of melphalan and response to treatment in multiple myeloma. Fernberg JO; Johansson B; Lewensohn R; Mellstedt H Eur J Cancer; 1990 Mar; 26(3):393-6. PubMed ID: 2141499 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. Ardiet C; Tranchand B; Biron P; Rebattu P; Philip T Cancer Chemother Pharmacol; 1986; 16(3):300-5. PubMed ID: 3516430 [TBL] [Abstract][Full Text] [Related]
26. Pharmacology of intravenous melphalan in patients with multiple myeloma. Brox L; Birkett L; Belch A Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169 [No Abstract] [Full Text] [Related]
27. Is more better? Cooper MR Cancer Invest; 1992; 10(1):93-4. PubMed ID: 1735015 [No Abstract] [Full Text] [Related]
28. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Osterborg A; Ehrsson H; Eksborg S; Wallin I; Mellstedt H Eur J Cancer Clin Oncol; 1989 May; 25(5):899-903. PubMed ID: 2737222 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379 [TBL] [Abstract][Full Text] [Related]
30. High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure. Pecherstorfer M; Zimmer-Roth I; Weidinger S; Irsigler K; Halbmayer WM; Ulrich W; Fischer M; Baumgartner G Clin Investig; 1994 Jul; 72(7):522-5. PubMed ID: 7981581 [TBL] [Abstract][Full Text] [Related]
31. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide-Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma. Huledal G; Ruiz-Garcia A; Kawakatsu S; Wang X; Sjöberg P; Gullbo J; Pekar D; Norin S; Jerling M J Clin Pharmacol; 2024 Feb; 64(2):240-252. PubMed ID: 37752623 [TBL] [Abstract][Full Text] [Related]
33. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361 [TBL] [Abstract][Full Text] [Related]
34. A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Berenson JR; Hilger JD; Yellin O; Boccia RV; Matous J; Dressler K; Ghazal HH; Jamshed S; Kingsley EC; Harb WA; Noga SJ; Nassir Y; Swift RA; Vescio R Ann Hematol; 2014 Jan; 93(1):89-98. PubMed ID: 24135804 [TBL] [Abstract][Full Text] [Related]
35. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT; J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Pinguet F; Martel P; Fabbro M; Petit I; Canal P; Culine S; Astre C; Bressolle F Anticancer Res; 1997; 17(1B):605-11. PubMed ID: 9066587 [TBL] [Abstract][Full Text] [Related]
37. [High-dose melphalan in patients with multiple myeloma]. Moreau P; Le Bonniec M; Harousseau JL Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762 [TBL] [Abstract][Full Text] [Related]
38. Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. Shulman LN; Buswell L; Kalish LA; Coleman CN Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):541-3. PubMed ID: 8005813 [TBL] [Abstract][Full Text] [Related]
39. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]